Back

Targeting replication stress in neuroblastoma by exploiting the synergistic potential of second generation RRM2 and CHK1 inhibitors

Nelen, I. H.; Leys, S.; Bekaert, S.-L.; De Vloed, F.; Martens, F.; Raj, A. P. E.; Ohmura, S.; Vleminckx, L.; Grunewald, T. G. P.; Van Roy, N.; De Wilde, B.; Speleman, F.; Van Hemelryk, A.; Depestel, L.; Durinck, K.

2025-03-02 cancer biology
10.1101/2025.02.26.640375 bioRxiv
Show abstract

Tumor cells often cope with elevated levels of replication stress (RS) causing increased dependency on ATR-CHK1 signalling. We previously presented RRM2, the regulatory component of the ribonucleotide reductase (RNR) enzyme, as novel dependency in neuroblastoma, in keeping with its role in RS resistance. We identified strong synergism for combined RRM2-CHK1 inhibition using the iron chelator triapine and prexasertib respectively. To obtain direct RNR targeting, we evaluated a novel inhibitor, TAS1553, specifically disrupting the RNR complex in this study. Treatment with TAS1553 impedes cell growth and induces enhanced RS, DNA damage and apoptosis. We demonstrated strong synergism between TAS1553 the CHK1 inhibitors prexasertib and SRA737 in both NB and sarcoma cell lines, underscoring the broad clinical potential of combinatorial RRM2-CHK1 inhibition. Transcriptome profiling demonstrated strong overlap between the different RRM2-CHK1 treatments and revealed differential expression of RNA splicing components, opening new perspectives for combination treatments using splicing inhibitors. Altogether, this study paves the way for further preclinical testing of second generation RRM2 and CHK1 inhibitors such as TAS1553 and SRA737 in neuroblastoma and sarcomas.

Published in Cell Death & Disease (predicted rank #14) · training set

Matching journals

The top 11 journals account for 50% of the predicted probability mass.

1
EMBO Molecular Medicine
○ 95 papers in training set
Top 0.1%
11.8%
Similar papers in this journal
2
Molecular Oncology
○ 55 papers in training set
Top 0.1%
7.8%
Similar papers in this journal
3
eLife
● 5828 papers in training set
Top 20%
6.2%
Similar papers in this journal
4
iScience
○ 1154 papers in training set
Top 5%
4.0%
Similar papers in this journal
5
Scientific Reports
○ 3612 papers in training set
Top 32%
3.2%
Similar papers in this journal
6
Cell Reports Medicine
○ 153 papers in training set
Top 0.9%
3.2%
7
Molecular Cancer Therapeutics
● 40 papers in training set
Top 0.3%
3.2%
8
Biomedicine & Pharmacotherapy
○ 42 papers in training set
Top 0.3%
3.2%
9
Frontiers in Oncology
○ 103 papers in training set
Top 1%
3.2%
10
Cancers
○ 213 papers in training set
Top 2%
2.6%
11
Life Science Alliance
● 285 papers in training set
Top 2%
2.6%
50% of probability mass above
12
Cell Reports
○ 1498 papers in training set
Top 15%
2.4%
13
Nature Communications
○ 5641 papers in training set
Top 40%
2.4%
Cell Death & Disease · published here
147 papers in training set
Top 1%
2.1%
15
Cell Chemical Biology
○ 94 papers in training set
Top 0.6%
2.1%
16
British Journal of Cancer
○ 49 papers in training set
Top 0.6%
2.1%
17
Neuro-Oncology
◐ 36 papers in training set
Top 0.3%
1.9%
18
Disease Models & Mechanisms
139 papers in training set
Top 1%
1.9%
19
Communications Biology
○ 993 papers in training set
Top 14%
1.7%
20
Frontiers in Pharmacology
○ 111 papers in training set
Top 2%
1.5%
21
The EMBO Journal
○ 309 papers in training set
Top 4%
1.3%
22
Journal of Experimental & Clinical Cancer Research
○ 25 papers in training set
Top 0.4%
1.3%
23
Cell Death Discovery
○ 58 papers in training set
Top 0.8%
1.3%
24
Cancer Letters
○ 35 papers in training set
Top 0.8%
1.1%
25
Antiviral Research
○ 50 papers in training set
Top 0.5%
1.1%
26
International Journal of Molecular Sciences
○ 494 papers in training set
Top 11%
1.1%
27
Cellular and Molecular Life Sciences
○ 96 papers in training set
Top 1%
1.1%
28
ACS Pharmacology & Translational Science
● 40 papers in training set
Top 0.7%
1.0%
29
Neoplasia
○ 23 papers in training set
Top 0.7%
1.0%
30
Pharmacological Research
○ 18 papers in training set
Top 0.5%
0.8%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.